THE Pennant Group, Inc.
PNTGHIGH VELOCITYFILING INTENSITYTHE Pennant Group, Inc. reads as an High Velocity (composite 70/100); Programmatic Roll-Up deploying $274M across 105 disclosed transactions, up 332% vs the prior cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
$274M
vs $63M in 2020–2022
Disclosed transactions
105
3/3 active fiscal years in window
Buyer archetype
Programmatic Roll-Up
High recurring acquisition cadence, usually with many smaller targets.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $356M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 34d
- 60 8-Ks
Target Probability
Issuers showing target-side patterns from filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
Pressure Watch
Issuers facing activism, governance, or control pressure
Distress Watch
Issuers showing financial-distress filing patterns
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 60 8-Ks
- 4 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $1.7B
- 10-Q 34d ago
- 2 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $204M · Peak count: 73
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 73 | $204M | $3M | N/A |
| 2024 | 17 | $48M | $3M | N/A |
| 2023 | 15 | $21M | $1M | N/A |
| 2022 | 8 | $10M | $1M | N/A |
| 2021 | 11 | $14M | $1M | N/A |
| 2020 | 14 | $39M | $3M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Tuck In25%
- Geographic Expansion25%
- Bolt On25%
- Horizontal Consolidation25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- tuck_in
- geographic_expansion
- bolt_on
- horizontal_consolidation
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We plan to continue to take advantage of the fragmented home health, hospice and senior living industries by being disciplined in acquiring strategic and underperforming operations within both our existing and new geographic markets.”
“The disciplined acquisition and integration of strategic and underperforming operations is a key element of our past success and is integral to our future growth plans.”
“strategy of acquiring strategic and underperforming operations in these highly fragmented markets will be an instrumental to our future growth”
“disciplined acquisition and integration of strategic and underperforming operations is a key element of our past success”
“proactive yet disciplined in acquiring strategic and underperforming operations with high upside potential”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
PNTG trades at a +12.3-turn premium to the Healthcare peer median of 12.9×.
- EV / Revenue
- 1.7×
- Net debt / EBITDA
- 2.4×
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
THE Pennant Group, Inc.PNTG | 25.2× | 1.7× | 2.4× | $1B | $274M |
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)72026-02-26
- 10-Q (quarterly)202026-05-06
- 8-K (event)602026-05-06
- Proxy / DEF 14A92026-03-31
- Activism (13D / DFAN / PREC)0N/A
Signals on file
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.